Corcept Therapeutics Resubmits NDA for Relacorilant in Cushing’s Syndrome

On June 17, 2026, Corcept Therapeutics announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant, a selective glucocorticoid receptor (GR) antagonist intended for the treatment of patients with Cushing’s syndrome. The resubmission follows a previous request from the FDA for additional analyses of data already included in the original filing. The application is supported by positive results from the pivotal Phase 3 GRACE trial, the Phase 3 GRADIENT trial, and long-term extension studies. Corcept highlights that relacorilant provides durable improvements in Cushing’s symptoms without the serious adverse events typically associated with current treatments, such as hypokalemia and adrenal insufficiency. The company expects the FDA to conduct a six-month review of the resubmitted application. Relacorilant is already approved under the brand name Lifyorli for platinum-resistant ovarian cancer. Corcept continues to advance its pipeline of cortisol modulators across various indications including ALS and liver disease.